An unknown Screening platform has flagged more than 95% of stage 1 cancers. The new study is published in Nature Communications Medicine. If validated by future studies, the approach offers a method to notice the third-leading cause of U.S. cancer deaths in 2020.
The new study which is in 139 stage 1 and 2 cancer patients and 184 controls is the first clinical test of a platform technology called high-conductance di-electrophoresis, developed at Moores Cancer Center at UC San Diego Health 12 years ago. It detects extracellular vesicles, which include tumor proteins that are released into circulation by cancer cells as part of a poorly understood intercellular communication network.
Artificial intelligence-enabled protein marker analysis is then used to predict the likelihood of malignancy. The approach detected 99.5 percent of stage 1 pancreatic cancers, as well as 74.4 percent of stage 1 ovarian cancer and 73.1% of pathologic stage 1A lethally aggressive serous ovarian adenocarcinomas, all with greater than 99% specificity, demonstrating the technology’s potential value in early cancer detection.
“They can cause real harm to otherwise healthy people when used for early-disease Screening due to unacceptably high false-positive rates that lead to diagnostic tests that are not only expensive but often dangerous,” Lippman said. Liquid biopsy tests produce promising results for cancer therapy monitoring and disease relapse, Lippman said, “but they can cause real harm to otherwise healthy people when used for early-disease Screening due to unacceptably high false-positive rates that lead to diagnostic tests that are not only expensive,